查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612521

良性前列腺增生药物市场：依产品、销售管道- 全球预测 2025-2030

Benign Prostatic Hypertrophy Drugs Market by Product (5-alpha-reductase Inhibitors, Alpha Blockers, Phosphodiesterase-5 Inhibitors), Sales Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

良性前列腺增生治疗市场2023年估值为51.5亿美元，预计到2024年将达到55亿美元，复合年增长率为6.97%，到2030年预计将达到82.6亿美元。

良性摄护腺增生（BPH）治疗市场的定义是旨在缓解男性前列腺非癌性增大引起的症状的药物，主要影响老年男性。由于人口老化、生活方式的改变以及改善尿流和减少相关症状的健康意识的增强，前列腺增生症的盛行率不断增加，因此对有效治疗解决方案的需求凸显。 BPH 治疗方法包括 α阻断剂、5-α 还原酶抑制剂、磷酸二酯酶 5 抑制剂和联合治疗，主要透过口服给药。最终使用领域主要是医院、诊所和提供老年人护理的家庭护理机构。关键的成长要素包括前列腺相关疾病的盛行率上升、给药技术的进步、医疗保健成本的上升以及更强有力的报销政策。然而，该市场面临诸如替代疗法的可用性、与良性前列腺增生药物相关的副作用以及严格的监管核准等限制，这可能会阻碍成长动力。随着新兴经济体的成长，由于医疗保健系统的改善、精准医学研究的进步以及副作用更少的新配方的开发，扩张的机会正在出现。公司应瞄准个人化治疗方法，并专注于教育医疗保健专业人员和患者了解新配方的好处和进步。必须注意已开发国家市场饱和、主要药品专利到期等问题。数位健康解决方案和药物开发策略联盟的创新工作可以提供竞争优势。市场竞争往往非常激烈，主要企业在进行策略性合併、收购和产品发布。因此，寻求成长的公司必须利用这些动态，探索市场利基，并确保合规性，以有效地利用不断扩大的机会。

主要市场统计
基准年[2023] 51.5亿美元
预计年份 [2024] 55亿美元
预测年份 [2030] 82.6亿美元
复合年增长率（%） 6.97%

市场动态：揭示快速发展的 BPH 药物市场的关键市场洞察

供需的动态交互作用正在改变良性前列腺增生药物的市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球良性摄护腺增生盛行率不断上升
    • 支持性监理政策提高市场核准效率
  • 市场限制因素
    • 良性前列腺增生药物的高成本和替代治疗的可用性
  • 市场机会
    • 良性摄护腺增生药物研发进展与创新
    • 加大新型给药技术研发投入
  • 市场挑战
    • 因安全问题而召回产品

波特五力：驾驭 BPH 药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对良性前列腺增生药物市场的影响

外部宏观环境因素在塑造良性前列腺增生药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解良性摄护腺增生治疗药物市场的竞争状况

对良性前列腺增生药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

良性前列腺增生药物市场中的 FPNV 定位矩阵供应商绩效评估

FPNV定位矩阵是评估良性前列腺增生药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划良性前列腺增生药物市场的成功之路

对良性前列腺增生治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球良性摄护腺增生盛行率不断上升
      • 支持性监理政策，提高市场核准效率
    • 抑制因素
      • BPH 药物高成本且替代治疗方法的可用性
    • 机会
      • BPH 药物开发的进展与创新
      • 加大新型给药技术研发投入
    • 任务
      • 因安全问题而召回产品
  • 市场区隔分析
    • 产品：加强研发开发下一代良性摄护腺增生治疗药物
    • 销售管道：网路药局业务成长加快
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章良性摄护腺增生药物市场：副产品

  • 5α-还原酶抑制剂
  • α阻断剂
    • 阿夫唑嗪
    • 多沙唑嗪
    • Tamsulosin
    • 特拉唑嗪
  • 磷酸二酯酶5抑制剂

第七章良性摄护腺增生药物市场：依销售管道

  • 医院药房
  • 网路药房
  • 零售药房
  • 专业药房

第八章北美和南美良性前列腺增生药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区良性摄护腺增生治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东、非洲前列腺增生药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Zydus Lifesciences 新型前列腺治疗胶囊获得美国FDA核准
    • Bluewater Vaccines 策略收购 ENTADFI 扩大良性前列腺增生的治疗选择
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Advin Health Care
  • Alembic Ltd.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • biolitec Holding GmbH & Co KG
  • Boston Scientific Corporation
  • CH Boehringer Sohn AG & Co. KG
  • Care Formulation Labs Pvt. ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Intas Pharmaceuticals Limited
  • Medifocus Inc.
  • Merck & Co., Inc.
  • Nymox Pharmaceutical Corporation
  • Onconetix, Inc.
  • Pfizer Inc.
  • Pharex Health Corporation
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • UNILAB, Inc.
  • Urologix, LLC
  • Zydus Lifesciences Limited
Product Code: MRR-CB04E056547E

The Benign Prostatic Hypertrophy Drugs Market was valued at USD 5.15 billion in 2023, expected to reach USD 5.50 billion in 2024, and is projected to grow at a CAGR of 6.97%, to USD 8.26 billion by 2030.

The market for Benign Prostatic Hypertrophy (BPH) drugs is typically defined by pharmaceutical products aimed at alleviating symptoms caused by the non-cancerous enlargement of the prostate gland in men, primarily affecting older adult males. The necessity for these drugs stems from the increasing prevalence of BPH due to demographic aging, lifestyle changes, and heightened health awareness, emphasizing the demand for effective therapeutic solutions that improve urinary flow and reduce associated symptoms. Applications of BPH drugs include alpha-blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, and combination therapies, primarily administered orally. The end-use segment predominantly covers hospitals, clinics, and home care settings that cater to geriatric care. Key growth influencers include the rising incidence of prostate-related disorders, technological advancements in drug delivery, increasing healthcare expenditure, and enhanced reimbursement policies. However, this market faces limitations such as the availability of alternative treatments, side effects associated with BPH drugs, and stringent regulatory approvals, which can impede growth dynamics. Opportunities for expansion are visible with the ongoing research in precision medicine and the development of novel formulations with lesser side effects, alongside growth in emerging economies due to improving healthcare systems. Companies should explore targeting personalized treatment approaches and focus on educating healthcare providers and patients about the benefits and advancements of newer drug formulations. Challenges like market saturation in developed regions and patent expirations of leading drugs require attention. Innovating around digital health solutions and engaging in strategic collaborations for drug development can offer competitive advantages. The market tends to be highly competitive with key players engaging in strategic mergers, acquisitions, and product launches. Thus, organizations aiming for growth should leverage these dynamics, seeking niche markets, and ensuring regulatory compliance to capitalize on expanding opportunities effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 5.15 billion
Estimated Year [2024] USD 5.50 billion
Forecast Year [2030] USD 8.26 billion
CAGR (%) 6.97%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Benign Prostatic Hypertrophy Drugs Market

The Benign Prostatic Hypertrophy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing global prevalence of benign prostatic hypertrophy
    • Supportive regulatory policies enhancing market approval efficiency
  • Market Restraints
    • High cost of BPH drugs and availability of alternate treatments
  • Market Opportunities
    • Advancements and innovation in BPH drug development
    • Increased investment in R&D for novel drug delivery technologies
  • Market Challenges
    • Product recalls due to safety concerns

Porter's Five Forces: A Strategic Tool for Navigating the Benign Prostatic Hypertrophy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Benign Prostatic Hypertrophy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Benign Prostatic Hypertrophy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Benign Prostatic Hypertrophy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Benign Prostatic Hypertrophy Drugs Market

A detailed market share analysis in the Benign Prostatic Hypertrophy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Benign Prostatic Hypertrophy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Benign Prostatic Hypertrophy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Benign Prostatic Hypertrophy Drugs Market

A strategic analysis of the Benign Prostatic Hypertrophy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Benign Prostatic Hypertrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Advin Health Care, Alembic Ltd., Asahi Kasei Corporation, Astellas Pharma Inc., biolitec Holding GmbH & Co KG, Boston Scientific Corporation, C.H. Boehringer Sohn AG & Co. KG, Care Formulation Labs Pvt. ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Intas Pharmaceuticals Limited, Medifocus Inc., Merck & Co., Inc., Nymox Pharmaceutical Corporation, Onconetix, Inc., Pfizer Inc., Pharex Health Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UNILAB, Inc., Urologix, LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hypertrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across 5-alpha-reductase Inhibitors, Alpha Blockers, and Phosphodiesterase-5 Inhibitors. The Alpha Blockers is further studied across Alfuzosin, Doxazosin, Tamsulosin, and Terazosin.
  • Based on Sales Channel, market is studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing global prevalence of benign prostatic hypertrophy
      • 5.1.1.2. Supportive regulatory policies enhancing market approval efficiency
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of BPH drugs and availability of alternate treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and innovation in BPH drug development
      • 5.1.3.2. Increased investment in R&D for novel drug delivery technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Product recalls due to safety concerns
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing R&D towards development next generation benign prostatic hypertrophy drug
    • 5.2.2. Sales Channel: Rising business growth across online pharmacies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Benign Prostatic Hypertrophy Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. 5-alpha-reductase Inhibitors
  • 6.3. Alpha Blockers
    • 6.3.1. Alfuzosin
    • 6.3.2. Doxazosin
    • 6.3.3. Tamsulosin
    • 6.3.4. Terazosin
  • 6.4. Phosphodiesterase-5 Inhibitors

7. Benign Prostatic Hypertrophy Drugs Market, by Sales Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies
  • 7.5. Specialty Pharmacies

8. Americas Benign Prostatic Hypertrophy Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Benign Prostatic Hypertrophy Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Benign Prostatic Hypertrophy Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Zydus Lifesciences Secures USFDA Approval for Novel Prostate Treatment Capsules
    • 11.3.2. Strategic Acquisition of ENTADFI by Blue Water Vaccines Inc. for Enhancing Treatment Options for Benign Prostatic Hyperplasia
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Advin Health Care
  • 4. Alembic Ltd.
  • 5. Asahi Kasei Corporation
  • 6. Astellas Pharma Inc.
  • 7. biolitec Holding GmbH & Co KG
  • 8. Boston Scientific Corporation
  • 9. C.H. Boehringer Sohn AG & Co. KG
  • 10. Care Formulation Labs Pvt. ltd.
  • 11. Eli Lilly and Company
  • 12. GlaxoSmithKline PLC
  • 13. Intas Pharmaceuticals Limited
  • 14. Medifocus Inc.
  • 15. Merck & Co., Inc.
  • 16. Nymox Pharmaceutical Corporation
  • 17. Onconetix, Inc.
  • 18. Pfizer Inc.
  • 19. Pharex Health Corporation
  • 20. Sanofi S.A.
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. UNILAB, Inc.
  • 23. Urologix, LLC
  • 24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023